http://rdf.ncbi.nlm.nih.gov/pubchem/patent/UA-114808-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 |
| filingDate | 2013-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a02521f8177d3d9db10b12604c10805b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1454fc74b644247baeb1914f97a5f577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8235210d4778ffe76368d00e7a407007 |
| publicationDate | 2017-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | UA-114808-C2 |
| titleOfInvention | PHARMACEUTICAL DIAGNOSTICS |
| abstract | The invention relates to the selective treatment of a patient with cancer, comprising the selective administration of a therapeutically effective amount of (S) -pyrrolidine-1,2-dicarboxylic acid 2-amide-1 - ({4-methyl-5- [2- (2,2 , 2-trifluoro-1,1-dimethylethyl) -pyridin-4-yl] -thiazol-2-yl} -amide) or a pharmaceutically acceptable salt thereof, to a patient on the basis that the patient has glutamine at position 859 of the catalytic subunit R (R3K) . |
| priorityDate | 2013-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457586568 |
Total number of triples: 14.